Oncolytics Biotech

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ONCY and other ETFs, options, and stocks.

About ONCY

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

CEO

Jared Kelly

CEOJared Kelly

Employees

Employees28

Headquarters

Calgary, Alberta

HeadquartersCalgary, Alberta

Founded

1998

Founded1998

Employees

Employees28

ONCY Key Statistics

Market cap

119.47M

Market cap119.47M

Price-Earnings ratio

-4.43

Price-Earnings ratio-4.43

Dividend yield

—

Dividend yield—

Average volume

944.17K

Average volume944.17K

High today

$1.19

High today$1.19

Low today

$1.14

Low today$1.14

Open price

$1.17

Open price$1.17

Volume

553.13K

Volume553.13K

52 Week high

$1.51

52 Week high$1.51

52 Week low

$0.3258

52 Week low$0.3258

ONCY News

TipRanks 4d

Promising Potential of Oncolytics Biotech’s Pelareorep in SCAC: Buy Rating with $5 Price Target

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Oncolytics Biotech. The associated price target remains the same with $5.00. Ele...

TipRanks 5d

Oncolytics Biotech Reports Promising Anal Cancer Data with Pelareorep

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 5d

Oncolytics reports updated results from study of pelareorep plus atezolizumab

Oncolytics (ONCY) Biotech announced updated results from the single-arm squamous cell anal carcinoma cohort of the GOBLET study evaluating pelareorep in combina...

Analyst ratings

83%

of 6 ratings

Buy

83.3%

Hold

16.7%

Sell

People also own

Based on the portfolios of people who own ONCY. This list is generated using Robinhood data, and it’s not a recommendation.